Covidien shares should be bought on pullbacks, says RBC Capital RBC Capital believes that Covidien's operating margin will bottom in FY14. The firm thinks the company's EPS growth can reach 10% or more in the near-term, but it believes this outlook is already reflected in the stock's valuation. It keeps a Sector Perform rating on the stock.
News For COV From The Last 14 Days
Check below for free stories on COV the last two weeks.